Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

[1]  I. Mittra,et al.  Abstract S2-02: Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial , 2013 .

[2]  Y. Maehara,et al.  Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. , 2013, Lung cancer.

[3]  B. Yaremko,et al.  Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. , 2013, Lung cancer.

[4]  L. Yip,et al.  Outcome and Prognostic Factors After Adrenalectomy for Patients with Distant Adrenal Metastasis , 2013, Annals of Surgical Oncology.

[5]  Suzanne E Dahlberg,et al.  Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  M. Ladanyi,et al.  Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas , 2013, Cancer.

[7]  R. Stahel,et al.  Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. , 2012, Lung cancer.

[8]  P. Lambin,et al.  Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  D. Gomez,et al.  Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. , 2012, International journal of radiation oncology, biology, physics.

[10]  Joe Y. Chang,et al.  Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer , 2012, Pulmonary medicine.

[11]  P. Okunieff,et al.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.

[12]  R. Weichselbaum,et al.  Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  S. Jabbour,et al.  A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. , 2011, Journal of thoracic disease.

[14]  H. Dienemann,et al.  Surgical treatment of oligometastatic non-small cell lung cancer. , 2010, Lung cancer.

[15]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[16]  P. Buettner,et al.  Meta-Analysis of Survival of Patients with Stage IV Colorectal Cancer Managed with Surgical Resection Versus Chemotherapy Alone , 2010, World Journal of Surgery.

[17]  B. Kavanagh,et al.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis , 2009, Acta oncologica.

[18]  R. Weichselbaum,et al.  An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease , 2008, Clinical Cancer Research.

[19]  G. Bepler,et al.  Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Abrams,et al.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[22]  R. Weichselbaum,et al.  Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. , 2004, International journal of oncology.

[23]  Harold I Feldman,et al.  Model Selection, Confounder Control, and Marginal Structural Models , 2004 .

[24]  J. Lunceford,et al.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.

[25]  A. Iwasaki,et al.  Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[26]  M. Kris,et al.  A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. , 2002, Lung cancer.

[27]  D. Miller,et al.  Surgical treatment of primary lung cancer with synchronous brain metastases. , 2001, The Journal of thoracic and cardiovascular surgery.

[28]  M. Riquet,et al.  Surgical management of non-small cell lung cancer with synchronous brain metastases. , 2001, Chest.

[29]  A. Bernard,et al.  Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. , 2001, The Annals of thoracic surgery.

[30]  T. Iizasa,et al.  Prognostic factors in surgical treatment of solitary brain metastasis after resection of non-small-cell lung cancer. , 1999, Lung cancer.

[31]  M. Wolfson,et al.  The cost of managing lung cancer in Canada. , 1995, Oncology.

[32]  D. Osoba,et al.  Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy. , 1994, Oncology.

[33]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Craig E. Grossman.  Non-small Cell Lung Cancer , 2016 .

[35]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[36]  Quynh-Thu Le,et al.  Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. , 2012, Clinical lung cancer.

[37]  G. Veronesi,et al.  Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. , 2007, The Annals of thoracic surgery.

[38]  R. Robinson,et al.  Economic Evaluation and Health Care Cost-utility analysis , 2006 .

[39]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.